GlassScriptPhysician profile
Thomas J Ferrari
NPI 1346249109
$2,293.32
in general payments reported to CMS, 2019-2025
32 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $355 · 2021: $425 · 2022: $283 · 2023: $266 · 2024: $327 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,067 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,066.61 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $463.66 | 2021-2025 | |
| Lilly USA, LLC | $198.49 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $175.37 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $156.36 | 2020-2025 | Fanapt |
| Astrazeneca Pharmaceuticals LP | $155.01 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $135.48 | 2020-2025 | Ozempic, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $129.58 | 2019-2020 | |
| Glaxosmithkline, LLC. | $115.46 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $110.08 | 2020-2025 | |
| Pfizer INC. | $61.73 | 2020-2024 | |
| Allergan, INC. | $59.10 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.81 | 2021 | |
| Exact Sciences Corporation | $47.13 | 2023-2024 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $43.06 | 2020-2023 | Injectafer |
| Janssen Pharmaceuticals, INC | $39.29 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.39 | 2024-2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $36.94 | 2021-2025 | Gvoke Hypopen |
| Eisai INC. | $31.41 | 2021 | |
| Phathom Pharmaceuticals, INC. | $31.37 | 2024-2025 | Voquezna |
| Amgen INC. | $29.27 | 2024-2025 | Repatha, Repatha |
| Biogen, INC. | $22.57 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $20.19 | 2025 | Ajovy |
| Bayer Healthcare Pharmaceuticals INC. | $17.43 | 2022 | |
| Galderma Laboratories, L.P. | $16.53 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.11 | 2022 | |
| Amarin Pharma, INC. | $14.98 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.59 | 2023 | Quviviq |
| Ardelyx, INC. | $14.23 | 2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.16 | 2023 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $13.37 | 2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $13.09 | 2019 | |
| Merck Sharp & Dohme LLC | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ferrari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.